Thymosin beta4 gene delivery in endothelial cells, mice, and rabbits
How the study was set up
Endothelial-cell assays and mouse and rabbit limb-ischemia models used viral vectors to increase thymosin beta4, with pathway-blocking comparisons.
What the researchers measured
Cell tube formation, capillary density, collateral vessels, and limb perfusion were measured while PI3K/Akt and Rho pathways were inhibited.
How to read this evidence
Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.
Results in context
The experiments concern gene delivery and signaling dependencies. They do not directly test administration of a commercial TB-500 peptide or clinical treatment of poor circulation.
What this does not establish
Gene delivery of full-length thymosin beta4 is not administration of a TB-500 retail vial; animal ischemia results do not establish human benefit.
This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.
Publication & source
Why this paper is included
The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.
Publication indexing
Journal Article · Research Support, Non-U.S. Gov't